Glimigrand-MV 1.3 Tablet SR
Marketer
D Earth Pharmaceuticals Private Limited
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Glimigrand-MV 1.3 Tablet SR
Diabex Duo 1.3 SR tablets are classified as antidiabetic medications. This dual-action formulation manages type 2 diabetes in adults by regulating blood glucose. Diabex Duo 1.3 SR should be ingested with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication is one component of a comprehensive diabetes management plan, encompassing a balanced diet, regular physical activity, and weight management as directed by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is the most prevalent side effect, characterized by sweating, lightheadedness, headache, and tremors. Recognizing and managing these symptoms is vital. Regular meals and readily available glucose sources (e.g., sugary snacks, fruit juice) are essential preventative measures. Alcohol consumption increases hypoglycemia risk and should be avoided. Additional potential side effects include altered taste perception, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Prior heart conditions should be disclosed to your doctor before commencing treatment. Pregnant or lactating individuals require medical consultation before use. Regular blood glucose monitoring is necessary, along with potential blood tests to assess blood cell counts and liver function.
Primary Ingredients of Glimigrand-MV 1.3 Tablet SR
No text provided to rephrase.
Uses of Glimigrand-MV 1.3 Tablet SR
Managing type 2 diabetes
Major Benefits of Glimigrand-MV 1.3 Tablet SR:
Administer this medication precisely as prescribed by your physician, adhering to the specified dosage and treatment period. Ingest the Glimigrand-MV 1.3 Tablet SR whole; avoid chewing, crushing, or breaking. Consume on an empty stomach.
Common Side effects of Glimigrand-MV 1.3 Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Glimigrand-MV 1.3 Tablet SR:
Administer this medication precisely as prescribed by your physician, adhering to the specified dosage and treatment length. Ingest the entire tablet without chewing, crushing, or breaking it. Consume Glimigrand-MV 1.3 Tablet SR on an empty stomach.
How Glimigrand-MV 1.3 Tablet SR works:
Glimigrand-MV 1.3 extended-release tablets contain a triple-action formulation for diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glimigrand-MV 1.3 Tablet SR and alcohol is inadvisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
The use of Glimigrand-MV 1.3 Tablet SR during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Glimigrand-MV 1.3mg tablet is likely not safe for use while breastfeeding. Available human data indicates potential transfer of the medication into breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The use of Glimigrand-MV 1.3 Tablet SR is likely unsafe for individuals with kidney impairment and should be avoided. Medical advice is recommended. Furthermore, this medication is unsuitable for patients experiencing severe kidney dysfunction.
LiverCAUTION
Exercise caution when prescribing Glimigrand-MV 1.3 Tablet SR to individuals with hepatic impairment; dosage modification may be necessary. Consult a physician. For patients exhibiting mild to moderate liver dysfunction, initiate treatment with a reduced Glimigrand-MV 1.3 Tablet SR dosage; its use is contraindicated in those with severe liver disease.
What if you forget to take Glimigrand-MV 1.3 Tablet SR :
Should you forget a Glimigrand-MV 1.3 Tablet SR dose, administer it immediately upon recollection. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Glimigrand-MV 1.3 Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes Management |
3,018 People bought this recently